Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe
Authors Verleger K, Penrod JR, Manley Daumont M, Solem C, Luo L, Macahilig C, Hertel N
Received 18 July 2019
Accepted for publication 10 December 2019
Published 15 January 2020 Volume 2020:12 Pages 23—33
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Giorgio Lorenzo Colombo
Katharina Verleger, 1 John R Penrod, 2 Melinda Manley Daumont, 3 Caitlyn Solem, 4 Linlin Luo, 4 Cynthia Macahilig, 5 Nadine Hertel 6
1Pharmerit International, Berlin, Germany; 2Bristol-Myers Squibb, Princeton, NJ, USA; 3Bristol-Myers Squibb, Braine-L’alleud, Belgium; 4Pharmerit International, Bethesda, MD, USA; 5Medical Data Analytics, Parsippany, NJ, USA; 6Bristol-Myers Squibb, Uxbridge, UK
Correspondence: Katharina Verleger
Pharmerit International, Krausenstr 8, Berlin 10117, Germany
Tel +49 30 3080 7024
Purpose: Advanced non-small-cell lung cancer (aNSCLC; stage IIIB/IV) presents a substantial clinical burden to society; reliable estimates of its economic burden are lacking. Therefore, this study aimed to quantify real-world health care resource utilization (HCRU) and costs of patients with squamous (SQ) and non-SQ (NSQ) aNSCLC who received two or more lines of treatment (2L+) in Europe, and to describe cost-predictors.
Methods: The LENS (Leading the Evaluation of Non-squamous and Squamous NSCLC) retrospective chart review study collected data from 2L+ patients with aNSCLC diagnosed between 07/2009 and 08/2011 (wave 1) or 07/2010 and 09/2012 (wave 2) in France, Germany, Italy, Spain, England, the Netherlands, and Sweden. Patients were followed from diagnosis through most recent visit/death. A weighted average of country-specific unit costs (2018 Euro) was applied to systemic anti-cancer therapy usage and HCRU (hospital/emergency department visit, surgery, radiotherapy, ancillary care, biomarker testing) to determine the total cost from aNSCLC diagnosis to death. Generalized linear models (gamma distribution, log link) were used to assess clinical and demographic predictors.
Results: Of 973 2L+ aNSCLC patients, median overall survival (OS) was 1.5 years from advanced diagnosis (range: 0.2– 5.3; median OS: 1.4 [SQ], 1.6 [NSQ]), 79.0% died during follow-up. Weighted mean total per-patient costs were € 21,273, ranging from € 17,761 (England) to € 30,854 (Sweden), and € 15,446 (SQ) to € 26,477 (NSQ). Systemic drug costs comprised 77.4% of total costs. Insurance status, presence of epidermal growth factor receptor (EGFR) mutation, SQ histology, age, alcohol abuse, and year of diagnosis were significant predictors for lower total costs per patient-month, Eastern Cooperative Oncology Group performance status (ECOG PS) ≥ 1 and country for higher costs.
Conclusion: In the era pre-immunotherapy, HCRU and costs were substantial in aNSCLC 2L+ patients, with most of the costs accrued prior to start of 2L. NSQ patients incurred significantly higher total costs than SQ patients in all participating countries.
Keywords: carcinoma, non-small-cell lung, observational study, cost of illness, health care costs
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]